|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Coronavirus disease 2019(COVID-19):a clinical update显示文摘Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)has posed a significant threat to global health.It caused a total of 80868 confirmed cases and 3101 deaths in Chinese mainland until March 8,2020.This novel virus spread mainly through respiratory droplets and close contact.As disease progressed,a series of complications tend to develop,especially in critically ill patients.Pathological findings showed representative features of acute respiratory distress syndrome and involvement of multiple organs.Apart from supportive care,no specific treatment has been established for COVID-19.The efficacy of some promising antivirals,convalescent plasma transfusion,and tocilizumab needs to be investigated by ongoing clinical trials. | Min Zhou Xinxin Zhang Jieming Qu | 2020 | Frontiers of Medicine2020，14，2： | 15 |
| 2 | Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2^(pos)subjects显示文摘Increasing numbers of SARS-CoV-2-positive(SARS-CoV-2^(pos))subjects are detected at silent SARS-CoV-2 infection stage(SSIS).Yet,SSIS represents a poorly examined time-window wherein unknown immunity patterns may contribute to the fate determination towards persistently asymptomatic or overt disease.Here,we retrieved blood samples from 19 asymptomatic and 12 presymptomatic SARS-COV-2^(pos)subjects,47 age/gender-matched patients with mild or moderate COVID-19 and 27 normal subjects,and interrogated them with combined assays of 44-plex CyTOF,RNA-seq and Olink.Notably,both asymptomatic and presymptomatic subjects exhibited numerous readily detectable immunological alterations,while certain parameters including more severely decreased frequencies of CD107a^(low)classical monocytes,intermediate monocytes,non-classical monocytes and CD62L^(hi)CD8^(+)Tnaive cells,reduced plasma STC1 level but an increased frequency of CD4^(+)NKT cells combined to distinguish the latter.Intercorrelation analyses revealed a particular presymptomatic immunotype mainly manifesting as monocytic overactivation and differentiation blockage,a likely lymphocyte exhaustion and immunosuppression,yielding mechanistic insights into SSIS fate determination,which could potentially improve 5ARS-CoV-2 management. | Shanhe Yu Caixia Di Shijun Chen Mingquan Guo Jiayang Yan Zhaoqin Zhu Li Liu Ruixue Feng Yinyin Xie Ruihong Zhang Juan Chen Mengxi Wang Dong Wei Hai Fang Tong Yin Jinyan Huang Saijuan Chen Hongzhou Lu Jiang Zhu Jieming Qu | 2021 | Cell Research2021，31，11： | 4 |
| 3 | Statistical control of low frequency knock in machine tool gearbox production 显示文摘 | Qu Liangsheng Zhang Hanfu Shen Yudi Wan Jieming | 1987 | Mechanism and Machine Theory J IFToMM1987，22，3： | 1 |
| 4 | Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)was reported at the end of 2019 as a worldwide health concern causing a pandemic of unusual viral pneumonia and many other organ damages,which was defined by the World Health Organization as coronavirus disease 2019(COVID-19).The pandemic is considered a significant threat to global public health till now.In this review,we have summarized the lessons learnt during the emergence and spread of SARS-CoV-2,including its prototype and variants.The overall clinical features of variants of concern(VOC),heterogeneity in the clinical manifestations,radiology and pathology of COVID-19 patients are also discussed,along with advances in therapeutic agents. | Dong Wei Yusang Xie Xuefei Liu Rong Chen Min Zhou Xinxin Zhang Jieming Qu | 2023 | Frontiers of Medicine2023，17，6： | 0 |
| 5 | Executive summary of Chinese expert consensus for topical application of anti-microbial agents for lower respiratory tract infection in adults显示文摘In recent years,with the increased prevalence of multi-drug resistant(MDR)bacterial infection and chronic pulmonary infection,the topical application of anti-microbial agents,mainly inhaled antibiotics,has come back to clinical practice.Several formulations for nebulization and dry powder inhaler(DPI)have been approved for inhaled anti-infective therapy.Meanwhile,evidence and experience have been accumulated in the use of anti-microbial agents delivered via airway.However,the available studies in this field are heterogenous in the study population,drug delivery route and dosages.The efficacy and safety of inhaled anti-infective therapy in various types of lower respiratory tract infections(LRTIs)need to be evaluated.Moreover. | Jing Zhang Qijian Cheng Yi Huang Hong Fan Guoxiang Lai Xiangdong Mu Wei Sha Danyang She Ning Shen Xin Su Jinfu Xu Feng Ye Xinlun Tian Tiantuo Zhang Hua Zhou Youning Liu Lixian He Heping Xiao Bei He Yi Shi Xiangyan Zhang Bin Cao Jieming Qu on behalf of Pulmonary Infection Assembly of Chinese Thoracic Society | 2022 | Chinese Medical Journal2022，135，22： | 0 |
| 6 | Atrial of arbidol hydrochloride in adults with COVID-19显示文摘Background: To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods: This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results: A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled;66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64]vs. 42.4% [14/33];difference of conversion rate 27.9%;95% confidence interval [CI], 7.7%-48.1%;P=0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 daysvs. 12.0 days;hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060,P=0.006), symptom of fever (median 3.0 daysvs. 12.0 days;HR: 18.990, 95% CI: 5.350-67.410,P<0.001), as well as hospitalization (median 12.5 daysvs. 20.0 days;P<0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 daysvs. 14.5 days;P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions: SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events. | Jingya Zhao Jinnong Zhang Yang Jin Zhouping Tang Ke Hu Hui Sun Mengmeng Shi Qingyuan Yang Peiyu Gu Hongrong Guo Qi Li Haiying Zhang Chenghong Li Ming Yang Nian Xiong Xuan Dong Juanjuan Xu Fan Lin Tao Wang Chao Yang Bo Huang Jingyi Zhang hi Chen Qiong He Min Zhou Jieming Qu | 2022 | Chinese Medical Journal2022，，13： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员